Navigation Links
TetraQ recognized for toxicology services
Date:5/16/2008

TetraQ, the integrated preclinical contract research provider based at The University of Queensland (UQ), has attained Good Laboratory Practice (GLP) recognition for its toxicology services after satisfying rigorous internationally-benchmarked criteria.

The additional accreditation from the National Association of Testing Authorities (NATA) for another of its key laboratories means that as well as GLP bioanalytical services, TetraQ can provide local and international clients with GLP compliant toxicology services including genotoxicity, dose range-finding, acute and repeat-dose studies.

TetraQ's Executive Director, Professor Maree Smith, said the GLP accreditation for its toxicology and ADME laboratories had now positioned TetraQ as the leading integrated preclinical service provider to the Australian biopharmaceutical industry.

TetraQ's decision to offer toxicology services, including toxicokinetics, allows us to leverage our strong track record in fully-validated bioanalytical method development and sample analysis, Professor Smith said.

We are delighted to be able to offer our clients in Australia and overseas an extended, internationally accredited service delivery which includes acute and chronic toxicology services, said Professor Smith.

These toxicology services include cytotoxicity assays, genotoxicity assays - bacterial mutation (Ames) tests; mouse lymphoma assay; mammalian erythrocyte micronucleus testing; dose range finding; safety pharmacology (cardiovascular, central nervous and respiratory systems); off-target screening; and hERG binding assays.

TetraQ has state-of-the-art facilities and equipment which meet stringent quality and testing standards to conduct toxicology studies that can be recognized by international regulatory authorities.

GLP recognition is required for regulatory submissions on later-stage toxicology studies, and because we have designed our early-stage servic
'/>"/>

Contact: Rose-Marie Pennisi
communications@uq.edu.au
61-733-467-374
Research Australia
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Blue Cross and Blue Shield Initiatives Recognized for Increasing Patient Safety and Efficiency
2. Health Advocate Recognized by Inc. 500 as One of the Nations Fastest Growing Private Companies
3. J.D. Power and Associates Reports: CIGNA HealthCare Recognized for Call Center Customer Satisfaction Excellence For a Second Consecutive Year
4. J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas
5. Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction
6. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
7. J.D. Power and Associates Reports: Rush-Copley Medical Center Recognized for Third Consecutive Year for Providing an Outstanding Inpatient Experience
8. AstraZeneca Recognized as One of Working Mothers 100 Best Companies for the Sixth Consecutive Year
9. Blue Cross and Blue Shield Association Nationally Recognized by BusinessWeek and AARP for Creating a Unique Workplace Environment for New and Mature Employees
10. Higher death rates in kidney patients with newly recognized disease
11. For Second Year Beryl Recognized as a Tech Titan, One of Texas Fastest- Growing Technology Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/17/2010)... sepsis, and other potentially deadly infections long has focused ... But new research from the University of Utah and ... overeager inflammatory response to infection may help save more ... in Science Translational Medicine , researchers led by ... professor of internal medicine and director of the Molecular ...
(Date:3/17/2010)... March 17 Marianjoy Rehabilitation ... Planning, John Brady , DHA, has been ... Persons with Disabilities Task Force. The Task Force ... to determine what changes, recommendations, and innovations may ... for persons with disabilities. These recommendations will then ...
(Date:3/17/2010)... -- The National Association of Professional Insurance Agents (PIA) has named Louisiana Congressman Charlie Melancon its 2010 Legislator of the ... ... , ... ... ...
(Date:3/17/2010)... -- City Harvest Food Council members and chefs ... Caminos), Lou Elrose (Wildwood Barbeque), Ivan ... Green Table), and Jorge Collazo (SchoolFood executive ... Tuesday March 16, 2010 , for lunch to ... Nutrition Act with priorities outlined by the NYC Alliance ...
(Date:3/17/2010)... of cancer treatment, skin care may seem like a ... Wilmot Cancer Center knew that skin issues were a ... therapy, and through research she discovered that routine advice ... , Her findings, which have been published in the ... change locally and across the country. , "We,ve had ...
Breaking Medicine News(10 mins):Health News:Targeting blood vessels, immune system may offer way to stop infection-caused inflammation 2Health News:Targeting blood vessels, immune system may offer way to stop infection-caused inflammation 3Health News:Marianjoy Vice President Named to Illinois' Disabilities Task Force 2Health News:Professional Insurance Agents Name Rep. Charlie Melancon 2010 Legislator of the Year 2Health News:Professional Insurance Agents Name Rep. Charlie Melancon 2010 Legislator of the Year 3Health News:Professional Insurance Agents Name Rep. Charlie Melancon 2010 Legislator of the Year 4Health News:City Harvest Food Council Chefs Meet With Harlem Students For Lunch & Travel to Washington to Ask Congress to Invest in Child Nutrition 2Health News:City Harvest Food Council Chefs Meet With Harlem Students For Lunch & Travel to Washington to Ask Congress to Invest in Child Nutrition 3Health News:City Harvest Food Council Chefs Meet With Harlem Students For Lunch & Travel to Washington to Ask Congress to Invest in Child Nutrition 4Health News:Nurses' research settles a common cancer concern: Skin care 2Health News:Nurses' research settles a common cancer concern: Skin care 3
... theory for how delusions arise and why they persist. ... an in-depth analysis of patients with certain delusions and ... the frontal lobe and right hemisphere of the human ... the right hemisphere, leads to the over compensation by ...
... Directors,of The Procter & Gamble Company (NYSE: PG ... on the Common Stock and on the Series A and,Series ... payable on,or after February 17, 2009 to shareholders of record ... The company has been paying dividends without ...
... 13 Born no larger than a ballpoint pen at ... been named the 2009 National Ambassador for the March of ... Leesburg, Virginia, was born very early at 25 weeks, weighing ... given only a 5 percent chance of survival. During her ...
... most states neglect preventing tobacco-caused illness , , TUESDAY, Jan. ... the U.S. government consistently failing grades for not protecting ... the American Lung Association,s State of Tobacco Control ... states failed to enact critical policy measures, such as ...
... Blood Drain NEW YORK, Jan. 13 New York ... York City, Long Island, Hudson Valley and New Jersey) ... Hospital demand for blood (needed for emergency care and ... blood donation have been below forecast. Blood supplies ...
... to patients and medical work to qualified employees. In ... Neeltje van den Berg and coauthors from Greifswald and ... edition of Deutsches rzteblatt International ( Dtsch ... in the age structure in Germany has had major ...
Other Medicine News:Health News:Delusions associated with consistent pattern of brain injury 2Health News:Delusions associated with consistent pattern of brain injury 3Health News:Micro-Preemie Survives to Become March of Dimes 2009 National Ambassador 2Health News:Micro-Preemie Survives to Become March of Dimes 2009 National Ambassador 3Health News:U.S. Flunks on Tobacco Control Report Card 2Health News:U.S. Flunks on Tobacco Control Report Card 3Health News:U.S. Flunks on Tobacco Control Report Card 4Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 2Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 3Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 4Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 5
(Date:3/17/2010)... states to settle a whistleblower lawsuit that exposed an alleged kickback scheme by the pharmaceutical company to boost its sales of Kadian, a prescription painkiller. , ... ... ... ... "Patients need to know their doctors are prescribing drugs ...
(Date:3/17/2010)... 12 month follow up data from real world patients demonstrated long term clinical efficacy of the company,s Genous Bio-engineered R stent. , ... ... ... ... Margo Klomp , M.D., of the Academic Medical Center (AMC) in ...
(Date:3/17/2010)... DIEGO , March 17 ... announced that it has initiated a pivotal Phase ... controlled-release formulation of hydrocodone without acetaminophen.  ZX002 is ... severe pain in individuals who require around-the-clock opioid ... the most widely prescribed drug in the ...
Breaking Medicine Technology:Whistleblower Kickback Case Against Alpharma Results In $42.5 Million Recovery for U.S. and States 2Whistleblower Kickback Case Against Alpharma Results In $42.5 Million Recovery for U.S. and States 3Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 2Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 3Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 4Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone 2Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone 3Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone 4The Secret of Happiness 49884 1The Secret of Happiness 49884 2The Secret of Happiness 49884 3First Coast Medicare to Provide Case by Case Reimbursement for the Renessa 28R 29 Treatment for Incontinence in Women 49879 1First Coast Medicare to Provide Case by Case Reimbursement for the Renessa 28R 29 Treatment for Incontinence in Women 49879 2First Coast Medicare to Provide Case by Case Reimbursement for the Renessa 28R 29 Treatment for Incontinence in Women 49879 3Mercy Health Plans Launches MercyOne Connect 28TM 29 49874 1Mercy Health Plans Launches MercyOne Connect 28TM 29 49874 2
... VRUS ), Roche (SWX: ROG) and InterMune, Inc. ... have been dosed in an innovative clinical,trial in patients ... (run in centers in Australia and New Zealand) is ... molecules in the absence,of interferon., The initial study ...
... NOVATO, Calif., Nov. 10 Raptor,Pharmaceuticals Corp. ... today announced that the Company has entered ... d,Angers ("CHU d,Angers") of France to,evaluate Raptor,s ... Phase II clinical trial in patients with ...
Other Medicine Technology:Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 2Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 3Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 4Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 5Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 2Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 3Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 4Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 5Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease 6
QIAvac 96 is designed for efficient processing of QIAGEN 96-well plates....
Holder for QIAGEN 96-well plates, for use with QIAvac 96;...
For monitoring vacuum pressure, suitable for use with all QIAvac manifolds;...
DNA/RNA preparation in 8-multi channels...
Medicine Products: